We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…
Arianna15.02.2022
FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…
Sina Kohlbrenner06.01.2022
Back in 2017, when we first met Andreas Katopodis, he had the vision to build a company that translates breakthrough science in the field of…
Sina Kohlbrenner17.12.2021
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…
Sina Kohlbrenner26.10.2021
We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…
Sina Kohlbrenner23.06.2021
Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…
Sina Kohlbrenner21.06.2021
Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…
Sina Kohlbrenner20.04.2021
We are very proud to announce that Synendos Therapeutics has raised a USD 21M series A co-led by Kurma Partners and Sunstone Life Science Ventures.…
Sina Kohlbrenner11.11.2020
Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has…
Sina Kohlbrenner17.09.2020
